RAB26

Across TCGA pan-cancer cohorts, RAB26 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB26 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB26 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where RAB26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.427	0.780	.002	23	view →
PDAC	OS	Median	III,IV	0.252	0.864	.003	7	view →
LSCC	DFS	Median	All	1.000	0.337	.010	4	view →
GBM	OS	Median	All	0.890	0.675	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB26–HNSC (DFS)

Open the HNSC breakdown →